Apoptosis-inducing factor (AIF) represents a caspase-independent apoptotic pathway in the cell, and a mitochondrial localization sequence-truncated AIF (AIFD1-120) can be relocated from the cytoplasm to the nucleus and exhibit a constitutive proapoptotic activity. Here, we generated a chimeric immuno-AIF protein, which comprised an HER2 antibody, a Pseudomonas exotoxin translocation domain and AIFD1-120. Human Jurkat cells transfected with the immuno-AIF gene could express and secrete the chimeric protein, which selectively recognized HER2-overexpressing tumor cells and was endocytosed. Subsequent cleavage of truncated AIF from immuno-AIF and its release from the internalized vesicles resulted in apoptosis of tumor cells. Intramuscular injection of the immuno-AIF gene caused significant suppression of tumors and substantially prolonged mice survival in an HER2-overexpressing xenograft tumor model. Our study demonstrates the feasibility of the immuno-AIF gene as a novel approach to treating cancers that overexpress HER2. Gene Therapy (2006) 13, 313-320.
Introduction
HER2/ErbB2, a human epidermal growth factor receptor 2-related tyrosine kinase, which is almost undetectable in normal adult tissues, is widely overexpressed on the surface of many types of human tumors, especially those of the breast, ovary and stomach. [1] [2] [3] Patients with HER2-overexpressing cancers have an unfavorable prognosis, in the form of a shorter relapse time, a poor clinical outcome and a low survival rate. [4] [5] [6] Thus, the different expression of HER2 in normal cells and tumor cells, together with its clear involvement in pathogenesis and aggressiveness of tumor growth, [7] [8] [9] makes HER2 one of the most attractive targets for specific tumor therapy, particularly metastatic and minor foci after excision of the primary tumor. [10] [11] [12] [13] Apoptosis-inducing factor (AIF) is a recently discovered apoptosis executioner, which is believed to mediate caspase-independent apoptosis in several types of cells. [14] [15] [16] Mammalian AIF precursor consists of an N-terminal mitochondrial localization sequence (MLS, aa1À100), a spacer sequence (aa101-121), a FAD-binding domain (aa122-262 and aa400-477), an NADH-binding domain (aa263-399) and a C-terminal domain (aa478-613) associated with the proapoptotic activity of AIF. 17, 18 As a phylogenetically old flavoprotein, AIF is normally confined to the mitochondrial intermembrane space, probably acting as an NADH-oxidoreductase to catalyze electron transfer in the mitochondrial respiratory chain. 19, 20 In response to lethal signaling, AIF molecules are translocated out of the mitochondrial membrane through the cytosol to the nucleus, where they bind to DNA and provoke peripheral chromatin condensation, large-scale DNA fragmentation (approximately 50 kb) and cytotoxicity. [21] [22] [23] Studies have indicated that the oxidoreductase activity of AIF is not required for its proapoptotic action. 14 The strongly positive electrostatic potential at the surface of the AIF protein is responsible for its DNA-binding activity, which is independent of DNA sequence and crucial for cell death. 18, 24 The mechanisms of AIF-mediated chromatin condensation and DNA fragmentation in cell death have not been fully elucidated. Proposed mechanisms include the following: AIF may bind to DNA and increase the susceptibility of DNA to latent nucleases; AIF may recruit proteases and nucleases that cause chromatin condensation and degradation; and AIF could itself possess some cryptic nuclease activity.
Once released from mitochondria, AIF can initiate and mediate caspase-independent apoptosis, a process that does not need the participation of cytosolic factors and that cannot be abolished by intrinsic caspase inhibitors or antiapoptotic proteins, for example, bcl-2.
14 Moreover, knockout of AIF gene is lethal in mouse embryos, indicating that there is critical caspase-independent apoptosis during a very early stage of mammalian development. 25 AIF-mediated apoptosis is involved in the physiological and pathological death of most eukaryocytes, [26] [27] [28] [29] [30] including neuronal and non-neuronal cells. 31, 32 Accumulation of AIF in the extramitochondrial compartment, particularly in the nucleus, leads to caspase-independent apoptosis. Thus, AIF is a potential candidate for the treatment of various cancers through the induction of apoptosis.
In the present work, we constructed a novel chimeric proapoptotic protein, immuno-AIF, consisting of a HER2 antibody, a Pseudomonas exotoxin A (PE)-derived translocation domain (PEII) and an MLS-truncated AIF (AIFD1-120). We expected that, owing to the high affinity of e23sFv for the extracellular domain of HER2, the recombinant immuno-AIF molecule would selectively bind HER2-overexpressing cancer cells and be internalized. 33, 34 As mediated by PEII, the protein would undergo an endosomal cleavage and release to the cytosol a C-terminal peptide, containing part of PEII and AIFD1-120. 35, 36 Consequently, the released AIFD1-120, in which the N-terminal MLS and the spacer sequence were deleted, would be relocated from the cytosol to the nucleus, and kill cancer cells by inducing apoptosis. Our previous studies have shown that the similar chimeras, immunocaspases and immunogranzyme B, killed HER2-overexpressing tumor cells effectively. [37] [38] [39] Here, we evaluated the antitumor activity of immuno-AIF both in vitro and in vivo on HER2-overexpressing tumor models with the aim of generating a potential candidate for gene therapy.
Results
Expression of AIFD1-120 and PEII/AIFD1-120 induce apoptosis in transfected HeLa cells
The chimeric immuno-AIF gene was generated by sequentially fusing the coding sequences of a signal peptide, a single-chain HER2 antibody (e23sFv), a PE translocation domain (PE aa253-358/364) and AIFD1-120. As reported, an endosomal cleavage would always occur between Arg279 and Gly280 of PE translocation domain, so the immuno-AIF protein would be processed to a cytosolic C-terminal peptide containing PEII (280-358/364) and AIFD1-120 ( Figure 1) . 35, 36 In our study, a primary goal was to establish whether the AIFD1-120 showed significant proapoptotic activity, and whether PEII (280-358/364) peptide interfered with such an activity.
The genes of AIFD1-120 and PEII (280-358/364)/ AIFD1-120 were generated and cloned into a pIRES2-EGFP vector, which coexpressed the gene of interest and GFP by producing a bicistronic transcript. HeLa cells were transfected transiently with pIRES2-EGFP-AIFD1-120, pIRES2-EGFP-PEII (280-358/364)/AIFD1-120 and the null vector as control. Western blotting analysis of cell lysates showed the expression of AIFD1-120 and its fusion proteins in addition to a detectable expression of endogenous wild-type AIF (Figure 2a) . Indirect immunofluorescent staining revealed that, in control cells, AIF is sequestered in mitochondria (visualized as punctuate red spots) separated from the nucleus. However, in AIFD1-120-and its fusion gene-transfected cells, overexpressed AIF variants were dispersed in the cytosol and nucleus, which was associated with substantial morphological abnormalities (Figure 2b ). Annexin V-FITC staining revealed that the percentages of apoptotic cells in the transfectants of AIFD1-120, PEII(280-358)/ AIFD1-120 or PEII(280-364)/AIFD1-120 genes were 14.6, 18.3, and 17.3%, respectively, compared to 0.5% in the control cells, suggesting exposure of phosphatidylserine on the outer leaflet of the plasma membrane (Figure 2c ). Typical features of apoptosis as detected by electron microscopy were plasma membrane blebbing, peripheral chromatin condensation and nuclear shrinkage ( Figure  2d ). The proliferation of AIFD1-120-and its fusion genetransfected HeLa cells was much lower than that of the non-or mock-transfected cells (Figure 2e ). Thus, we concluded that the expression of recombinant human AIF could induce apoptosis in transfected HeLa cells. The proapoptotic activity of PEII/AIFD1-120 was comparable to that of AIFD1-120, suggesting that PE peptide fused in the N-terminal of AIFD1-120 did not affect this action.
Secreted immuno-AIF proteins from modified Jurkat cells selectively kill HER2-overexpressing tumor cells in vitro
Human lymphoma Jurkat cells were stably transfected with immuno-AIF genes and were expected to express and secrete the corresponding chimeric proteins. As shown in Figure 3a , an 830 bp fragment of the PEII/ AIFD1-120 fusion gene, which was not present in parental Jurkat cells, was amplified from the genomic DNA and cDNA of immuno-AIF gene-modified Jurkat cells, but not from those of the control cells. This finding provides evidence for the presence of immuno-AIF transcripts in the transfected cells and indicates that the immuno-AIF gene was integrated into the host genome. Western blot analysis confirmed the expression and the secretion of immuno-AIF proteins (Figure 3a) .
Jurkat cells producing immuno-AIF proteins showed normal proliferation and viability relative to parental Jurkat cells (data not shown), suggesting that the secreted chimeric protein does not adversely affect HER2-negative Jurkat cells. HER2-overexpressing human Secreted immuno-AIF proteins contribute to suppressed tumor growth and prolonged survival in an in vivo HER2-overexpressing mouse tumor model
The in vivo antitumor activity of immuno-AIF was evaluated in mouse xenograft models of HER2-overexpressing SKBR-3 cells and HER2-negative HeLa cells. As shown in Figure 4 , the growth of SKBR-3, but not HeLa tumors in mice treated intramuscularly (i.m.) with pCMV-immuno-AIF for 3 weeks was significantly suppressed (Figure 4a ; P ¼ 0.00002 by ANCOVA test) Secreted tumoricidal HER2 antibody/AIF chimera C-J Yu et al and the survival time of mice treated with pCMVimmuno-AIF was distinctly longer than that of the control group (Figure 4b ; P ¼ 0.0216 by the log-rank test), whereas almost no tumor regression or survival prolongation was observed in mice with xenograft of HeLa cells (Figure 4a ; P ¼ 0.00002 by ANCOVA test). These findings suggest that i.m. administration of immuno-AIF gene can suppress HER2-overexpressing tumor growth specifically and effectively, presumably via HER2-targeted proapoptotic activity of immuno-AIF secreted by genetically modified muscle cells. Immunohistochemical staining confirmed that the secreted immuno-AIF protein was selectively located in tumor tissues of the treatment group. While in other tissues, such as the heart, liver, spleen, lung, kidney and in the tumor tissue of control mice, immunohistochemical staining with an AIF antibody was negligible despite a detectable expression of endogenous AIF, suggesting a poor localization of immuno-AIF on those tissues ( Figure  4c) . Moreover, TUNEL analysis detected numerous apoptotic cells in tumor tissues of mice treated with the pCMV-immuno-AIF constructs (Figure 4d) . Thus, immuno-AIF proteins exhibit a selective and enduring distribution in HER2-overexpressing tumor tissue, and kill tumor cells efficiently by triggering apoptosis or even necrosis (data not shown). 
Discussion
The crystal structures of mouse and human AIF have provided much information about the function of AIF. Studies identifying molecules in AIF-mediated apoptosis pathway, the characterization of their actions, 29, [40] [41] [42] [43] and the confirmation of the critical role of this pathway in normal and in pathologic models have proceeded rapidly. 44, 45 These studies have extended our understanding of the proapoptotic activity of AIF, making it a potential candidate for cancer gene therapy. Our immuno-AIF strategy, in which a novel chimeric protein was generated by sequentially fusing a signal peptide, an anti-HER2 single-chain antibody and a PE translocation domain to a truncated AIF, may enable selective destruction of cancer cells that overexpress HER2.
To detect whether mammalian cells can produce targeted immuno-AIF, HeLa cells were transfected with pCMV-immuno-AIF genes and stained with FITClabeled anti-AIF antibody. Strong positive staining in perinuclear Golgi region of the transfected cells was observed when incubated with an anti-AIF antibody Immuno-AIF, which selectively targets HER2-overexpressing cells, is internalized in endosomes, where the chimeric protein undergoes a furin-mediated cleavage between Arg279 and Gly280 of the original PE peptide, releasing its C-terminal peptide into the cytosol. This peptide, which comprises a PE sequence (PE aa280-364) and AIFD1-120, then induces apoptosis. Our in vitro results revealed that immuno-AIF killed HER2-overexpressing tumor cells, but not HER2-negative tumor cells or normal cells when they were cultured in the medium of immuno-AIF-modified cells. The in vivo antitumor activity of immuno-AIF was also demonstrated in a murine xenograft model of HER2-overexpressing tumors since it inhibited tumor growth and prolonged mice survival without damaging the normal tissues.
In contrast to previously reported immunotoxins, immuno-AIF consists mainly of humanized antibodies and human endogenous proteins. Therefore, immuno-AIF treatment should result in relatively weak immunogenicity and minor systemic toxicity in repeated administrations. Moreover, unlike the immunocaspase constructs, immuno-AIF should be particularly effective for tumor cells deficient in caspase-dependent apoptotic pathway. 37, 38 Many studies have revealed a costimulation between the caspase-dependent and the AIF-dependent pathways during apoptosis. 19, 22, 25, 40, 45 In our study, the release of cytochrome c was observed in PEII (280-358/ 364)/AIFD1-120 gene-transfected cells (data not shown), suggesting that caspases might be activated and then cooperate with AIF to mediate tumor cell apoptosis.
Studies on the crystal structure of mammalian AIF have revealed that the proapoptotic action of AIF is not dependent on its oxidoreductase activity, which may enable us to develop a smaller AIF variant with conserved proapoptotic activity. 20, 21, 24 A properly designed immuno-AIF of smaller size may have enhanced translocation efficiency and proapoptotic effects. Comparison of PBS, liposome, retroviral and adenoviral delivery systems for the immunocaspase-6 gene indicates that liposomes may be the least appropriate vehicle for continuous treatment in vivo, due to their presumed toxicity in nude mice. 38 Although more effective and less toxic delivery systems for the immuno-AIF gene need to be investigated, our study demonstrates the feasibility of this immuno-AIF strategy as an approach to treating HER2-overexpressing cancers and cancers with deficient caspase-mediated apoptotic pathway.
Materials and methods

DNA construction
The human AIF gene was amplified by PCR using cDNA prepared from human Jurkat cells lines. Recombinant immuno-AIF was generated by sequential fusion of the genes of a signal peptide (Met-Lys-His-Leu-Trp-PhePhe-Leu-Leu-Leu-Val-Ala-Ala-Pro-Arg-Trp-Val-LeuSer-), a single-chain HER2 antibody (sFv23e), a PE translocation domain (aa253-358 or aa253-364) and AIFD1-120 lacking the MLS of AIF. The immuno-AIF gene was cloned into a pCMV plasmid. To test the effect of the residual PE translocation domain on truncated AIFD1-120, we cloned the genes of a partial PE translocation domain (aa280-358 and aa280-364) and fused them to the 5 0 -end of the AIFD1-120 gene. The resulting PEII/AIFD1-120 fusion gene was cloned into pcDNA3 and pIRES2-EGFP (BD Biosciences Clontech). All constructs were confirmed by DNA sequencing.
Cell culture and transfection
Human breast tumor cell line SKBR-3, human ovarian tumor cell line SKOV-3, human cervical carcinoma cell line HeLa, human umbilical vein endothelial cell line ECV-304, human laryngeal tumor cell line Hep2 and human lymphoma cell line Jurkat were maintained in Dulbecco's modified Eagle's medium or RPMI 1640 medium supplemented with 10% fetal bovine serum at 371C and in an atmosphere of 5% CO 2 . At 24 h before transfection, cells were seeded in 12-well plates at a density of 1 Â 10 5 cells/well. Transfection was performed at 70-80% cell confluence with LipofectAMINE 2000 (Invitrogen) using a standard procedure. For transient expression, cells were harvested at 24, 48 and 72 h after transfection. For stable expression, transfected cells were selected using G418 medium (800 mg/ml) for 3-4 weeks.
Detection of apoptosis Indirect immunofluorescence staining. HeLa cells cultured on coverslips were fixed, permeabilized and stained for AIF. A polyclonal anti-AIF antibody (Santa Cruz, CA, USA) was used to detect AIF expression, and a rabbit anti-goat IgG conjugated to biotin and SABS-Cy3 were used to amplify and visualize the staining. The expression of EGFP (green) and AIF (red) in transfected cells was assessed by observation with laser confocal microscopy.
Electron microscopy. Transfected HeLa cells pellets were fixed for 2 h at 41C with 2.5% glutaraldehyde in 0.1 mol/l sodium phosphate buffer, pH 7.4. They were washed three times, and fixed again in 1% osmic acid in phosphate buffer, followed by scraping, dehydration and embedding. Ultrathin sections mounted on a 200 mesh grid were examined in a GEM-2000EX electron microscope.
Annexin V-FITC staining. Transfected HeLa cells were collected and washed, and Annexin V-FITC and PI staining was performed according to a standard protocol of BD PharMingen. Cells were then analyzed by flow cytometry.
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Cell viability assay
For MTT assay, HeLa cells transfected with the PEII/ AIFD1-120 gene were cultured in 96-well plates for 24-96 h, and incubated with 20 ml of 1.5 mg/ml MTT per well for 4 h, followed by the addition of 150 ml of DMSO. OD 490 nm values were determined using a Sunrise microplate reader (Tecan, Groedig, Austria). Each assay was performed in triplicate and the experiment was repeated on at least three separate occasions.
PCR amplification
Genomic DNA was extracted and cDNA was prepared from Jurkat cells stably transfected with pCMV vector and pCMV-immuno-AIF after G418 selection. Using 5 0 -tccgcggccgcgaaaggcggcagccctg-3 0 as the upstream primer and 5 0 -ctccaagcttctaaagtctccaatct-3 0 as the downstream primer, a fusion gene, which encompassed the sequence encoding PE aa253-358/364 and that coding AIF aa121-291, was amplified from these genomic DNA and cDNA templates.
Western blotting
The lysates of AIFD1-120-transfected cells and the serum-free supernatant from the cells stably transfected with immuno-AIF were concentrated and analyzed by SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membranes (Amersham Biosciences) and incubated with biotin-labeled goat anti-human AIF primary antibody (1 : 500), and a horseradish peroxidase (HRP)-conjugated avidin-biotin complex amplification reagent (Jackson ImmunoResearch). Gel bands were developed with ECL Western blotting detection reagents (Amersham Biosciences).
In vitro cytotoxicity of immuno-AIF
HER2-overexpressing SKBR-3 and SKOV-3 cells, as well as ECV-304 and Hep2 cells that rarely express HER2 were seeded into 12-well plates and fed continuously with the supernatant of Jurkat cells modified to secrete immuno-AIF protein or mock-transfected Jurkat cells. For assessment of internalization and nuclear translocation of the killer protein, the above-treated SKBR-3 cells were stained with anti-AIF antibody and Cy3-labeled second antibody, while the nuclei were visualized by DAPI staining. To corroborate a caspase-independent proapoptotic activity of immuno-AIF, the supernatants of cultured Jurkat cells that secreted immuno-AIF or previously reported immunocaspase-3 37 were prepared. SKBR-3 cells were cultured and were fed continuously with the above supernatants, with or without 20 mmol/l caspase inhibitor, Z-VAD-FMK (Calbiochem). All targeted cells were trypsinized and counted at various times, and the percentages of killed cells were calculated from the following expression: (1Àthe number of cells cocultured with the supernatant of Jurkat-immuno-AIF or Jurkat-immunocaspase-3/the number of cells cocultured with the supernatant of untransfected Jurkat cell) Â 100%.
In vivo antitumor activity of immuno-AIF BALB/c athymic mice (4-6 weeks old, 18-22 g weight) were inoculated subcutaneously with 2 Â 10 6 human SKBR-3 breast cancer cells or HeLa cervical cancer cells. When tumors grew to a diameter of 5-7 mm within 2 weeks, mice were randomly assigned to groups (n ¼ 8) and received six 5 mg LipofectAMINE-encapsulated pCMV-immuno-AIF or pCMV vector (one treatment every 3 days). Tumor growth was monitored by measuring with a caliper two perpendicular diameters every 3 days. The volume of the tumor was calculated from the following formula: tumor volume ¼ ðwidthÞ 2 Âlength=2
Immunohistochemistry
Various tissues from the above-treated mice were collected and fixed in 10% neutral-buffered formalin, processed in paraffin, sectioned at 4 mm, and then dewaxed, hydrated and incubated in methanol-H 2 O 2 for 20 min to remove endogenous peroxidase. Tissue sections were then stained with the AIF antibody according to the immunohistochemical HRP-conjugated avidin-biotin complex procedure described above. TU-NEL analysis was performed according to the manufacturer's protocol (Oncogene).
